The results of this study are consistent with potentially effective results obtained with the administration of SGLT2 inhibitors, showing that HF-related rehospitalizations are more likely to be avoided if SGLT2 inhibitors are prescribed, regardless of the BI. The gene discussed is SLC5A2; the disease is hydrops fetalis.